Ex-smoker Michael Douglas Has Throat Cancer

Article

Michael Douglas faces his toughest role yet: a real-life cancer patient. The 65-year-old ex-smoker is preparing for an eight-week treatment regimen that will include radiation and chemotherapy.

Michael Douglas faces his toughest role yet: a real-life cancer patient. The 65-year-old ex-smoker is preparing for an eight-week treatment regimen that will include radiation and chemotherapy. The good news, according to Dr. Robert Haddad, an oncologist at the Dana-Farber Cancer Institute, is that Douglas is expected to make a full recovery, even though his cancer is believed to be in an advanced state.

The road to recovery will not be easy; following the chemotherapy and radiation treatment, Douglas will likely need to be fed from a tube for some time, as swallowing will be difficult. Upon a full recovery, Douglas will also need to make some life adjustments. In addition to never smoking again, he will also need to steer clear of second-hand smoke and alcohol.

Douglas was very open about his half-a-pack-a-day habit, which he kicked in 2006. The Academy Award-winning actor recently completed a sequel to the 1987 hit, Wall Street, which is due out in September. Douglas won the Oscar for Best Actor for his portrayal of the calculating, reptilian financial executive Gordon Gekko.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.